BeOne Medicines
ONC
#769
Rank
A$45.14 B
Marketcap
A$435.16
Share price
0.20%
Change (1 day)
17.18%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2026 (TTM): A$1.12 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are A$5.73 Billion. In 2025 the company made an earning of A$0.68 Billion, an increase over its 2024 earnings that were of -A$0.8 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.12 B62.4%
2025 A$0.68 B-186.57%
2024 -A$0.8 Billion-52.95%
2023 -A$1.7 Billion-32.52%
2022 -A$2.52 Billion24.39%
2021 -A$2.02 Billion-13.21%
2020 -A$2.33 Billion72.69%
2019 -A$1.35 Billion36.01%
2018 -A$0.99 Billion616.83%
2017 -A$0.14 Billion-15.24%
2016 -A$0.17 Billion107.91%
2015 -A$78.37 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-A$0.23 Billion-121.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-A$25.47 Million-102.40%๐Ÿ‡บ๐Ÿ‡ธ USA